Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration

Andrew R. Clark, Michael Ohlmeyer

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)
344 Downloads (Pure)


Protein phosphatase 2A (PP2A) is a highly complex heterotrimeric enzyme that catalyzes the selective removal of phosphate groups from protein serine and threonine residues. Emerging evidence suggests that it functions as a tumor suppressor by constraining phosphorylation-dependent signalling pathways that regulate cellular transformation and metastasis. Therefore, PP2A-activating drugs (PADs) are being actively sought and investigated as potential novel anti-cancer treatments. Here we explore the concept that PP2A also constrains inflammatory responses through its inhibitory effects on various signalling pathways, suggesting that PADs may be effective in the treatment of inflammation-mediated pathologies.
Original languageEnglish
Pages (from-to)181-201
JournalPharmacology & Therapeutics
Early online date1 Jun 2019
Publication statusPublished - 30 Sept 2019


  • Alzheimer’s disease
  • Cancer
  • Inflammation
  • Multiple sclerosis
  • Neurodegeneration
  • Protein phosphatase 2A


Dive into the research topics of 'Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration'. Together they form a unique fingerprint.

Cite this